Strategies de prevention du diabete de type 1: le point en 2003.

Clinical Trials as Topic; Diabetes Mellitus, Type 1/genetics/immunology/prevention & control; Humans; Immunosuppressive Agents/therapeutic use; Risk Factors

Abstract :

[en] Type 1 diabetes is caused by a progressive autoimmune destruction of insulin-producing B cells of the pancreatic islets of Langerhans. The autoimmune process begins years before the B-cell destruction becomes complete, thereby providing an opportunity for early intervention. Genetic susceptibility markers have been identified and autoantibody assays make possible the identification of individuals at high risk of the disease. Prevention strategies could be implemented in first-degree relatives of type 1 diabetic patients at high risk of developing the disease because of the presence of several autoantibodies. Alternatively, they may also be considered at time of clinical diagnosis of type 1 diabetes mellitus in order to maintain residual endogenous insulin secretion that markedly contributes to long-term better glycaemic stability. Thus, the goals of prevention are to preserve B cells during the preclinical period and/or after early diagnosis by modifying immunological pathogenic processes. Several molecules have been administered or are currently investigated to achieve this protection. This article summarizes the hopes and deceptions of previous clinical trials and describes the rationale and protocols of ongoing trials dealing with the prevention of type 1 diabetes.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Philips, Jean-Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Strategies de prevention du diabete de type 1: le point en 2003.

Alternative titles :

[en] Prevention strategies of type 1 diabetes: the focus in 2003

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

211-9

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 07 April 2009

Statistics

Number of views

483 (4 by ULiège)

Number of downloads

535 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Geenen V. - Le diabète insulinodépendant. Rev Med Liège, 1996, 51, 684-694.
Mauricio D, Mandrup-Pousen T. - Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes, 1998, 27, 1537-1543.
Yoon J, Jun H, Santamaria P. - Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity, 1998, 27, 109-122.
Naik R, Palmer J. - Preservation of beta-cell function in type 1 diabetes. Diabetes Rev, 1999, 7, 154-182.
Gottlieb P, Eisenbarth G. - Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med, 1998, 49, 391-405.
Rabinovitch A. - Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation ? Diabetes, 1994, 43, 613-621.
Geenen V, Lefèbvre P. - The intrathymic expression of insulin-related genes: implications for pathophysiology and prevention of Type 1 diabetes. Diabetes Metab Rev, 1998, 14, 95-103.
The Diabetes Control and Complications Trial Research Group. - The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
Krolewski A, Warram J, Rand L, et al. - Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med, 1987, 317, 1390-1398.
Gorus F, Pipeleers D. - Prospects for predicting and stopping the development of type 1 of diabetes. Best Pract Res Clin Endocrinol Metab, 2001, 15, 371-389.
Luyckx FH, Delcour S, Philips JC, Scheen AJ. - Le dosage des auto-anticorps anti-GAD et anti-IA2: une aide au diagnostic précoce du diabète de type 1. Rev Med Liège, 2000, 55, 169-175.
Thivolet C, Nicolino M, Monbeig S, et al. - The GRADI study. Combination of autoantibody markers and risk for development of type 1 diabetes: results from a large French cohort of family members. Diabetes Metab, 2002, 28, 279-285.
Gorus F. - Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev, 1997, 13, 247-274.
Vandewalle CL, Falorni A, Lernmark A, et al. - Associations of GAD65- and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. The Belgian Diabetes Registry. Diabetes Care, 1997, 20, 1547-1552.
Thivolet C. - Le diabète de type 1 á marche lente (diabète LADA). Diagnostic et prise en charge. Journ Annu Diabetol Hotel Dieu, 2001, 145-149.
Bach JF, Garchon HJ, van Endert P. - Genetics of human type 1 diabetes mellitus. Curr Dir Autoimmun. 2001, 4, 1-30.
Ronningen KS, Keiding N, Green A, EURODIAB ACE Study Group. Europe and Diabetes. - Correlations between the incidence of childhood-onset type I diabetes in Europe and HLA genotypes. Diabetologia, 2001, 44 (Suppl 3), B51-59.
Pietropaolo M, Becker DJ, LaPorte RE, et al. - Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes. Diabetologia, 2002, 45, 66-76.
Nerup J, Bendtzen K, Mandrup-Poulsen T. - A role for cyclosporin A in the treatment of insulin-dependent diabetes mellitus? Diabet Med, 1985, 2, 441-446.
Mahon JL, Dupre J, Stiller CR. - Lessons learned from use of cyclosporin for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion. Ann N Y Acad Sci, 1993, 696, 351-363.
Erlanger B. - Do we know the site of action of cyclosporin? Immunol Today, 1992, 13, 487-490.
Mandrup-Poulsen T, Molvig J, Andersen HU, et al. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group. Diabetes, 1990, 39, 204-210.
Philips JC, Scheen AJ. - Essai de prévention du diabète de type 1 par le nicotinamide: les leçons positives d'un essai clinique négatif (ENDIT). Rev Med Liège, 2002, 57, 672-675.
Scheen AJ. - Evidence-Based Medicine. Apport des essais cliniques contrôlès. Rev Med Liège, 2000, 55, 216-219.
Scheen AJ, Philips JC. - Insulinothérapie pour prévenir le diabète de type 1 chez des sujets apparentés à haut risque: résultats négatifs du "Diabetes Prevention Trial-Type 1". Rev Med Liège, 2002, 56, 536-538.
Philips JC, Scheen AJ et le Registre Belge du Diabète. - Essais de préservation des cellules B à la phase initiale du diabète de type 1: résultats négatifs avec l'insuline retard, mais prometteurs avec un anticorps monoclonal anti-CD3. Rev Med Liege, 2002, 57, 413-417.
Diabetes Prevention Trial - Type 1 Diabetes Study Group. - Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med, 2002, 346, 1685-1691.
Chaillous L, Lefevre H, Thivolet C. - Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet, 2000, 356, 545-549.
Pozzilli P, Pitocco D, Visalli N, et al. - No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia, 2000, 43, 1000-1004.
Chatenoud L, Thervet E, Primo J, et al. - Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA, 1994, 91, 123-127.
Herold KC, Hagopian W, Auger JA, et al. - Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med, 2002, 346, 1692-1698.
Vaarala O, Hyoty H, Akerblom HK. - Environmental factors in the aetiology of childhood diabetes. Diabetes Nutr Metab, 1999, 12, 75-85.
Ahmed T, Kamota T, Sumazaki R, et al. - Circulating antibodies to common food antigens in Japanese children with IDDM. Diabetes Care, 1997, 20, 74-76.
Holmes W. - Association of exposure to cow's milk protein and beta-cell autoimmunity (letter). JAMA, 1996, 276, 1800.
Vaarala O, Knip M, Paronen J, et al. - Cow's milk formula feeding induces primary immunization to insulin in infants at genetic risk for type I diabetes. Diabetes, 1999, 48, 1389-1394.
Vaarala O, Kaste J, Klemetti P, et al. - Development of immune response to orally administered cow milk protein in young children. Ann NY Acad Sci, 1996, 778, 429-430.
Pastore MR, Bazzigaluppi E, Belloni C, et al. - Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab, 2003, 88, 162-165.